Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

2.
3.
4.

A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.

Zhang Y, Tang L, Sun L, Bao J, Song C, Huang L, Liu K, Tian Y, Tian G, Li Z, Sun H, Mei L.

Acta Biomater. 2010 Jun;6(6):2045-52. doi: 10.1016/j.actbio.2009.11.035.

PMID:
19969111
5.

Role of integrated cancer nanomedicine in overcoming drug resistance.

Iyer AK, Singh A, Ganta S, Amiji MM.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802. doi: 10.1016/j.addr.2013.07.012. Review.

PMID:
23880506
7.

Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.

Assanhou AG, Li W, Zhang L, Xue L, Kong L, Sun H, Mo R, Zhang C.

Biomaterials. 2015 Dec;73:284-95. doi: 10.1016/j.biomaterials.2015.09.022.

PMID:
26426537
8.

Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.

Mattu C, Pabari RM, Boffito M, Sartori S, Ciardelli G, Ramtoola Z.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):463-72. doi: 10.1016/j.ejpb.2013.07.016.

PMID:
23916461
9.

Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.

Yang X, Iyer AK, Singh A, Milane L, Choy E, Hornicek FJ, Amiji MM, Duan Z.

Pharm Res. 2015 Jun;32(6):2097-109. doi: 10.1007/s11095-014-1602-1.

10.
11.

Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer.

Ren F, Chen R, Wang Y, Sun Y, Jiang Y, Li G.

Pharm Res. 2011 Apr;28(4):897-906. doi: 10.1007/s11095-010-0346-9.

PMID:
21184150
12.

Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.

Chavanpatil MD, Patil Y, Panyam J.

Int J Pharm. 2006 Aug 31;320(1-2):150-6.

PMID:
16713148
13.
14.

Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis.

Wang X, Beitler JJ, Wang H, Lee MJ, Huang W, Koenig L, Nannapaneni S, Amin AR, Bonner M, Shin HJ, Chen ZG, Arbiser JL, Shin DM.

PLoS One. 2014 Feb 25;9(2):e86369. doi: 10.1371/journal.pone.0086369.

15.

Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.

van Vlerken LE, Duan Z, Seiden MV, Amiji MM.

Cancer Res. 2007 May 15;67(10):4843-50.

16.

Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.

Talekar M, Ouyang Q, Goldberg MS, Amiji MM.

Mol Cancer Ther. 2015 Jul;14(7):1521-31. doi: 10.1158/1535-7163.MCT-15-0100.

17.
18.

Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy.

Acharya S, Dilnawaz F, Sahoo SK.

Biomaterials. 2009 Oct;30(29):5737-50. doi: 10.1016/j.biomaterials.2009.07.008.

PMID:
19631377
19.

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2000 May;6(5):2053-63.

20.

Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells.

Yu K, Zhao J, Zhang Z, Gao Y, Zhou Y, Teng L, Li Y.

Int J Pharm. 2016 Jan 30;497(1-2):78-87. doi: 10.1016/j.ijpharm.2015.11.033.

PMID:
26617314
Items per page

Supplemental Content

Support Center